Release Summary

CIK Treatment Extends Progression-free Survival of Glioblastoma Patients by 1.5 Times. The 'Immuncell-LC'-treated group demonstrated to be 30% higher in DCR without serious additional adverse effects.

Hanyang University Guri Hospital